Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Eikon Therapeutics announced that CEO Roger M. Perlmutter will participate in a key opinion leader event focusing on the therapeutic use of PARP inhibitors in oncology. The event, hosted by Cantor Fitzgerald, will feature expert discussions on current treatment landscapes and outcomes in cancers such as breast, ovarian, prostate, and pancreatic can…